Treatment Sequencing Strategies for Patients with Relapsed/ Refractory Multiple Myeloma
Panelists discuss strategies for sequencing bispecific antibodies with B-cell maturation antigen (BCMA)–targeted therapies, considering factors such as prior CAR T-cell treatment, the impact of relapse timing on treatment decisions, and approaches for managing high-risk cytogenetics and extramedullary disease in relapsed/refractory multiple myeloma (R/R MM).
EP: 1.Current Landscape of Relapsed/ Refractory Multiple Myeloma
EP: 2.Management of Relapsed/Refractory Multiple Myeloma with Bispecifics: MonumenTAL-2, MajesTEC-1, and MagnetisMM-3 trials
EP: 3.Bispecifics in Relapsed/ Refractory Multiple Myeloma: Combination Strategies, Stepping Up, and Treatment Dose Considerations
EP: 4.Treatment Sequencing Strategies for Patients with Relapsed/ Refractory Multiple Myeloma
EP: 5.Strategies for Community Adoption of Bispecifics into Treatment of Relapsed/ Refractory Multiple Myeloma
Video content above is prompted by the following:
- How do you approach sequencing bispecifics with other BCMA-targeted therapies, such as CAR T cells or antibody-drug conjugates?
- Can BCMA-targeting bispecifics be used in patients who have received prior BCMA-targeting CAR T-cell therapies?
- Might you consider a different target
- How has the emergence of CAR T-cell therapy revolutionized your approach to sequencing different treatment classes in R/R MM?
- In what ways does the time frame of relapse—early vs late—fundamentally alter your treatment-sequencing strategies for R/R MM patients?
- What specific factors do you consider when tailoring treatment approaches for early vs late relapse?
- How do the biological and clinical characteristics of early vs late relapse influence your decision-making process?
- Discuss strategies for managing patients with high-risk cytogenetics or extramedullary disease using bispecifics.
Recap: Recent Advances in the Treatment of Metastatic Castration-Sensitive Prostate Cancer
September 18th 2022Expert oncologists review key studies in the metastatic castration-resistant prostate cancer treatment landscape and discuss how evidence can be applied to clinical practice to improve patient outcomes.
Recap: Updates in Treatment of HER2-Positive Breast Cancer and Brain Metastases
July 16th 2022Sara A. Hurvitz, MD; Stefania Maraka, MD; and Ruta Rao, MD, discuss the evolving landscape of metastatic HER2+ breast cancer, highlighting recent clinical trials and the management of patients with brain metastases.
Recap: Emory Experts Review Treatment Strategies for Transplant-Ineligible Multiple Myeloma
June 20th 2022A panel of experts from Emory University review several key data updates in multiple myeloma from recent meetings and discuss how the data can be applied to clinical practice to improve patient outcomes.
